SG45486A1 - Pyrimidinedione pyrimidinetrione truazubeduione tetrahydro-quinazolinedione derivatives as alpha 1 adrenergic receptor antagonists - Google Patents

Pyrimidinedione pyrimidinetrione truazubeduione tetrahydro-quinazolinedione derivatives as alpha 1 adrenergic receptor antagonists

Info

Publication number
SG45486A1
SG45486A1 SG1996010018A SG1996010018A SG45486A1 SG 45486 A1 SG45486 A1 SG 45486A1 SG 1996010018 A SG1996010018 A SG 1996010018A SG 1996010018 A SG1996010018 A SG 1996010018A SG 45486 A1 SG45486 A1 SG 45486A1
Authority
SG
Singapore
Prior art keywords
truazubeduione
pyrimidinetrione
pyrimidinedione
tetrahydro
alpha
Prior art date
Application number
SG1996010018A
Other languages
English (en)
Inventor
Angel Guzman
Arturo Perez-Medrano
David J Morgans Jr
Eric B Sjogren
Francisco J Lopez-Tapia
Francisco X Talamas
Gary W Bantle
Jurg R Pfister
Saul Jaime-Figueroa
Todd R Elworthy
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG45486A1 publication Critical patent/SG45486A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SG1996010018A 1995-06-09 1996-06-07 Pyrimidinedione pyrimidinetrione truazubeduione tetrahydro-quinazolinedione derivatives as alpha 1 adrenergic receptor antagonists SG45486A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48918395A 1995-06-09 1995-06-09

Publications (1)

Publication Number Publication Date
SG45486A1 true SG45486A1 (en) 1998-01-16

Family

ID=23942748

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996010018A SG45486A1 (en) 1995-06-09 1996-06-07 Pyrimidinedione pyrimidinetrione truazubeduione tetrahydro-quinazolinedione derivatives as alpha 1 adrenergic receptor antagonists

Country Status (32)

Country Link
EP (1) EP0748800B1 (fr)
JP (1) JP2721147B2 (fr)
KR (1) KR100446877B1 (fr)
CN (1) CN1118459C (fr)
AR (1) AR003428A1 (fr)
AT (1) ATE201016T1 (fr)
AU (1) AU710754B2 (fr)
BR (1) BR9602705A (fr)
CA (1) CA2178548A1 (fr)
CO (1) CO4700472A1 (fr)
CZ (1) CZ290004B6 (fr)
DE (1) DE69612698T2 (fr)
DK (1) DK0748800T3 (fr)
ES (1) ES2157366T3 (fr)
GR (1) GR3036307T3 (fr)
HK (1) HK1013065A1 (fr)
HU (1) HU223594B1 (fr)
IL (1) IL118519A (fr)
MA (1) MA23899A1 (fr)
MY (1) MY113499A (fr)
NO (1) NO309424B1 (fr)
NZ (1) NZ286720A (fr)
PE (1) PE46497A1 (fr)
PL (1) PL188061B1 (fr)
PT (1) PT748800E (fr)
RU (1) RU2175322C2 (fr)
SA (1) SA96170263B1 (fr)
SG (1) SG45486A1 (fr)
TR (1) TR970073A2 (fr)
TW (1) TW340846B (fr)
UY (1) UY24257A1 (fr)
ZA (1) ZA964561B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6271234B1 (en) 1997-08-01 2001-08-07 Recordati S.A., Chemical And Pharmaceutical Company 1,4-disubstituted piperazines
DE69830045T2 (de) * 1997-10-31 2006-01-12 Daiichi Suntory Pharma Co., Ltd. Arylpiperidinopropanol und Arylpiperazinopropanol Derivate und dieselbe ent- haltende Pharmazeutika
US6083950A (en) * 1997-11-13 2000-07-04 Ranbaxy Laboratories Limited 1-(4-arylpiperazin-1-yl)-ω-[n-(α,ω-dicarboximido)]-alka nes useful as uro-selective α1-adrenoceptor blockers
DK0949250T3 (da) * 1998-03-30 2006-08-28 Hoffmann La Roche Fremgangsmåde til fremstilling af alpha1L-adrenoceptorantagonister
AU1979799A (en) * 1998-07-21 2000-02-14 Ranbaxy Laboratories Limited Arylpiperazine derivatives useful as uro-selective alpha-1-adrenoceptor blockers
BR9912318A (pt) * 1998-07-21 2001-05-02 Ranbaxy Lab Ltd Compostos de 1- (4-arilpiperazin-1-il) -w- [n- (ol, w -dicarboximido) ] alcanos de utilidade como bloqueadores uro-seletivos de 1 - adrenoceptor.
WO2000029386A1 (fr) 1998-11-12 2000-05-25 Merck & Co., Inc. Derives de la pyrimidinedione, antagonistes de l'adrenocepteur alpha 1a
US6358959B1 (en) 1999-01-26 2002-03-19 Merck & Co., Inc. Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
US6387909B1 (en) 1999-07-30 2002-05-14 Recordati S.A. Chemical And Pharmaceutical Company Thienopyranecarboxamide derivatives
US6306861B1 (en) 1999-07-30 2001-10-23 Recordati S.A. Chemical And Pharmaceutical Company Thienopyrancecarboxamide derivatives
GB2355457A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel spirotricyclic substituted azacycloalkane derivatives useful as alpha 1a adrenoceptor antagonists
GB2355456A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists
GB2355264A (en) 1999-09-30 2001-04-18 Merck & Co Inc Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists
GB2355263A (en) 1999-09-30 2001-04-18 Merck & Co Inc Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists
US6403594B1 (en) 1999-10-18 2002-06-11 Recordati, S.A. Chemical And Pharmaceutical Company Benzopyran derivatives
US6365591B1 (en) 1999-10-18 2002-04-02 Recordati, S.A., Chemical And Pharmacueticals Company Isoxazolecarboxamide derivatives
EP1255738B1 (fr) 2000-01-25 2012-03-07 Neurocrine Biosciences, Inc. Antagonistes du recepteur de la gonadoliberine et methodes associees
CZ20031698A3 (cs) * 2000-11-30 2003-11-12 Ranbaxy Laboratories Limited 1,4-Disubstituované piperazinové deriváty využitelné jako uro-selektivní alfa1-adrenoreceptorové blokátory
EP1414808A1 (fr) 2001-08-02 2004-05-06 Neurocrine Biosciences, Inc. 1,2,4-triazin-3,5-diones comme antagonistes du recepteur de l'hormone de liberation des gonadotrophines (gnrh)
DE10311065A1 (de) 2003-03-13 2004-09-23 Abbott Gmbh & Co. Kg Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung
US7687625B2 (en) 2003-03-25 2010-03-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
BRPI0413452A (pt) 2003-08-13 2006-10-17 Takeda Pharmaceutical composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
MY140489A (en) * 2003-12-26 2009-12-31 Eisai R&D Man Co Ltd 1,2-di (cyclic) substituted benzene compounds
GB0400290D0 (en) 2004-01-08 2004-02-11 Medivir Ab dUTPase inhibitors
AU2004318013B8 (en) 2004-03-15 2011-10-06 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1655288A1 (fr) * 2004-11-05 2006-05-10 Institut Pasteur Composés aryle-pyrimidyle, compositions pharmaceutiques les contenant et leur utilisation comme agents antimicrobiens
KR101274879B1 (ko) 2004-12-20 2013-06-14 에자이 알앤드디 매니지먼트 가부시키가이샤 1-시클로프로필메틸-4-[2-(3,3,5,5-테트라메틸시클로헥실)페닐]피페라진의 염 및 결정
EP2805953B1 (fr) 2004-12-21 2016-03-09 Takeda Pharmaceutical Company Limited Inhibiteurs de peptidase dipeptidyl
AU2006250388A1 (en) * 2005-05-25 2006-11-30 Eisai R & D Management Co., Ltd. Intermediate in production of [2-(3,3,5,5-tetramethylcyclohexyl)phenyl]piperazine compound
EP1942898B2 (fr) 2005-09-14 2014-05-14 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidyl peptidase permettant de traiter le diabete
JP5122462B2 (ja) * 2005-09-16 2013-01-16 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
DE102008030091B4 (de) * 2008-06-25 2011-03-03 Resprotect Gmbh Uracilderivate und deren Verwendung
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
RU2449994C1 (ru) * 2011-03-10 2012-05-10 Светлана Алексеевна Мещерякова 6-(4-бензилпиперазино)-1,3-диметилурацила дигидрохлорид, проявляющий биологическую активность
MY161170A (en) * 2011-03-18 2017-04-14 Corcept Therapeutics Inc Pyrimidine cyclohexyl glucocorticoid receptor modulators
GB201318886D0 (en) * 2013-10-25 2013-12-11 Givaudan Sa Improvements i or relating to organic compounds
SG11201807516UA (en) 2016-03-17 2018-09-27 Hoffmann La Roche 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar
CA3157658A1 (fr) * 2019-10-28 2021-05-06 Nippon Soda Co., Ltd. Compose 2,6-dioxo-3,6-dihydropyrimidine, bactericide agricole et horticole, nematicide et agent antifongique medical et veterinaire
US20240260575A1 (en) * 2021-04-28 2024-08-08 Nippon Soda Co., Ltd. Agricultural and horticultural fungicidal composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2727469A1 (de) * 1977-06-18 1978-12-21 Hoechst Ag Neue hexahydropyrimidine, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
JPH02184667A (ja) * 1989-01-11 1990-07-19 Meiji Seika Kaisha Ltd Ｎ，ｎ’―ジ置換ピペラジル誘導体及びそれを有効成分とする排尿障害改善剤
JPH0344379A (ja) * 1989-07-13 1991-02-26 Yamasa Shoyu Co Ltd Ｎ↑３―ピペラジノウラシル誘導体
JP2814600B2 (ja) * 1989-08-31 1998-10-22 正幸 石川 排尿障害治療剤
SG65570A1 (en) * 1992-02-25 1999-06-22 Recordati Chem Pharm Heterobicyclic compounds
FR2727682A1 (fr) * 1994-12-02 1996-06-07 Pf Medicament Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament

Also Published As

Publication number Publication date
ES2157366T3 (es) 2001-08-16
PE46497A1 (es) 1997-12-04
CN1118459C (zh) 2003-08-20
CZ290004B6 (cs) 2002-05-15
TW340846B (en) 1998-09-21
NZ286720A (en) 1998-08-26
ATE201016T1 (de) 2001-05-15
IL118519A0 (en) 1996-09-12
PT748800E (pt) 2001-10-30
AR003428A1 (es) 1998-08-05
NO309424B1 (no) 2001-01-29
GR3036307T3 (en) 2001-10-31
MY113499A (en) 2002-03-30
TR970073A2 (tr) 1997-02-21
RU2175322C2 (ru) 2001-10-27
DE69612698D1 (de) 2001-06-13
NO962412L (no) 1996-12-10
UY24257A1 (es) 2000-12-29
JPH09100269A (ja) 1997-04-15
AU5469096A (en) 1996-12-19
CO4700472A1 (es) 1998-12-29
CZ169696A3 (en) 1997-01-15
BR9602705A (pt) 1998-09-08
HUP9601529A3 (en) 2000-02-28
KR970001344A (ko) 1997-01-24
EP0748800A2 (fr) 1996-12-18
HK1013065A1 (en) 1999-08-13
AU710754B2 (en) 1999-09-30
CA2178548A1 (fr) 1996-12-10
SA96170263B1 (ar) 2006-05-23
MA23899A1 (fr) 1996-12-31
EP0748800B1 (fr) 2001-05-09
HU223594B1 (hu) 2004-09-28
PL188061B1 (pl) 2004-12-31
JP2721147B2 (ja) 1998-03-04
NO962412D0 (no) 1996-06-07
PL314635A1 (en) 1996-12-23
ZA964561B (en) 1996-12-09
DE69612698T2 (de) 2001-12-06
HU9601529D0 (en) 1996-07-29
HUP9601529A2 (hu) 1998-09-28
EP0748800A3 (fr) 1996-12-27
IL118519A (en) 1999-12-22
DK0748800T3 (da) 2001-08-27
KR100446877B1 (ko) 2004-11-06
CN1149051A (zh) 1997-05-07

Similar Documents

Publication Publication Date Title
SG45486A1 (en) Pyrimidinedione pyrimidinetrione truazubeduione tetrahydro-quinazolinedione derivatives as alpha 1 adrenergic receptor antagonists
PL338575A1 (en) 4-aminopyrrole(3,2-d)pyrimidines as antagonists of neuropeptide y receptor
IL123581A0 (en) Pyrimidine derivatives as 5HT2c- receptor antagonists
EP0822814A4 (fr) ANTAGONISTES DES RECEPTEURS ADRENERGIQUES ALPHA 1a
IL125030A0 (en) Vitronectin receptor antagonists
IL125033A0 (en) Vitronectin receptor antagonists
IL125034A0 (en) Vitronectin receptor antagonists
NZ307625A (en) 1-benzoyl-2-(indolyl-3-alkyl)-piperazine derivatives as neurokinin receptor antagonists
EP0763035A4 (fr) Antagonistes du recepteur de l'endotheline
HK1019149A1 (en) Indole derivatives useful as endothelin receptor antagonists
HU913074D0 (en) Fibrinogenic receptor antagonists
EP0833637A4 (fr) ANTAGONISTES DU RECEPTEUR ALPHA ADRENERGIQUE 1a
EP0831823A4 (fr) ANTAGONISTES DU RECEPTEUR ADRENERGIQUE ALPHA 1a
EP0755392A4 (fr) Antagonistes du recepteur adrenergique alpha1c
EP0766684A4 (fr) Antagonistes du recepteur de l'endotheline
HUP9902817A3 (en) Endothelin receptor antagonists
HU9602054D0 (en) Endothelin receptor antagonists
EP0854721A4 (fr) Antagonistes des recepteurs a l'endotheline
EP0831824A4 (fr) ANTAGONISTES DU RECEPTEUR ADRENERGIQUE ALPHA 1a
EP0768878A4 (fr) Antagonistes des recepteurs de l'endotheline
EP0841926A4 (fr) Antagonistes du recepteur d'endotheline
EP0853479A4 (fr) ANTAGONISTES DU RECEPTEUR ADRENERGIQUE ALPHA 1b
EP0841916A4 (fr) Antagonistes du recepteur d'endotheline
EP0868180A4 (fr) Antagonistes du recepteur d'endotheline
SI0856001T1 (en) Pyrimidine derivatives as 5ht2c receptor antagonists